| Activity |
| Catalytic type | Cysteine |
| Peplist | Included in the Peplist with identifier PL00100 |
| NC-IUBMB | Subclass 3.4 (Peptidases) >> Sub-subclass 3.4.22 (Cysteine endopeptidases) >> Peptidase 3.4.22.56
|
| Enzymology | BRENDA database |
| Proteolytic events | CutDB database (250 cleavages) |
| Activity status | human: active (Nicholson & Thornberry, 2004) mouse: active (Fujita et al., 2001)
|
| Physiology | One of the "executioner" caspases in mammalian cell apoptosis. |
| Knockout | Mice deficient in caspase-3 generated by homologous recombination were born at a lower frequency than expected, were smaller than their littermates and died at 1-3 weeks of age. Brain development in the deficient mice was profoundly affected (Kuida et al., 1996). The nature of the neurological defects in caspase-3 deficient mice has been further characterised by Eldadah et al., 2000 and Takahashi et al., 2001. |
| Pharmaceutical relevance | Relevant to apoptosis. 'The mapping of both the human caspase-3 gene and the locus responsible for an autosomal dominant, nonsyndromic form of hearing loss (DFNA24) to chromosome 4q35 suggests that the caspase-3-/- mice may represent a model of this human condition.' (Morishita et al., 2001). A non-peptidic inhibitor of caspase-3 and caspase-7 was effective in reducing cardiac ischemic injury in a rabbit model (Chapman et al., 2002). Caspase-3 is suggested to be a key effector of neuronal apoptosis in pneumococcal meningitis (Gianinazzi et al., 2003). Caspase-3 is reported to be crucial in reovirus-induced myocardial injury in mouse (DeBiasi et al., 2004). |
| Pathways |
KEGG | Alzheimer's disease |
|
KEGG | Amoebiasis |
|
KEGG | Amyotrophic lateral sclerosis (ALS) |
|
KEGG | Apoptosis |
|
KEGG | Colorectal cancer |
|
KEGG | Epithelial cell signaling in Helicobacter pylori infection |
|
KEGG | Hepatitis B |
|
KEGG | Herpes simplex infection |
|
KEGG | Huntington's disease |
|
KEGG | Legionellosis |
|
KEGG | MAPK signaling pathway |
|
KEGG | MicroRNAs in cancer |
|
KEGG | Natural killer cell mediated cytotoxicity |
|
KEGG | Non-alcoholic fatty liver disease (NAFLD) |
|
KEGG | p53 signaling pathway |
|
KEGG | Parkinson's disease |
|
KEGG | Pathways in cancer |
|
KEGG | Pertussis |
|
KEGG | Proteoglycans in cancer |
|
KEGG | Serotonergic synapse |
|
KEGG | TNF signaling pathway |
|
KEGG | Toxoplasmosis |
|
KEGG | Tuberculosis |
|
KEGG | Viral carcinogenesis |
|
KEGG | Viral myocarditis |
|
Other databases
| WIKIPEDIA | http://en.wikipedia.org/wiki/Caspase_3 |
| Cleavage site specificity |
Explanations of how to interpret the
following cleavage site sequence logo and specificity matrix can be found here. |
| Cleavage pattern | d/e/v/D gs/-/-/- (based on 701 cleavages) |